Daniel El Fassi

Daniel El Fassi

Auto-generated profile, based on publicly available information

Daniel El Fassi


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DFDaniel El Fassi
Daniel El Fassi
CNClaus H. Nielsen
Claus H. Nielsen
SBSteen J. Bonnema
Steen J. Bonnema
Hans HasselbalchHans Hasselbalch
Hans Hasselbalch
LHLaszlo Hegedüs
Laszlo Hegedüs
Context: Graves’ disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD. Objective/Design: The objective of this prospective, controlled, nonrandomized study was to investigate the effect of RTX in GD. Setting/Patients: We studied 20 outpatients referred to a university clinic with newly diagnosed (four with relapse) untreated GD. Ten received RTX (+RTX), whereas 10 did not (−RTX). Intervention: The patients received methimazole (MMI) for a median of 102 d (+RTX) and 110 d (−RTX) before the study. Patients in the +RTX group received 375 mg RTX/m2 iv on d 1, 8, 15, and 22, and all patients were withdrawn from methimazole (MMI) at d 22. Main Outcome Measures: We measured time to relapse of hyperthyroidism and changes in autoantibody levels. Results: Four patients in the +RTX group remained in remission with a median follow-up of 705 d (range, 435–904 d), whereas all the patients in the −RTX group had relapsed by d 393 (P < 0.05). All of the patients in remission had initial TRAb levels below 5 IU/liter (normal, <0.7 IU/liter). However, none of the five patients in the −RTX group with correspondingly low TRAb levels were in remission (P < 0.01). RTX treatment did not affect autoantibody levels to a greater extent than did MMI monotherapy. Two patients received glucocorticoids for joint pain after RTX therapy. Conclusions: RTX treatment may induce sustained remission in patients with GD with low TRAb levels. However, RTX did not affect autoantibody levels and seems ineffective in patients with high TRAb levels. At present, high cost, low efficacy, and potential side effects do not support use in uncomplicated GD.

11 April 2008 in Gut
Verified
Journal Article
Closed access
PDF file
DFDaniel El Fassi
Daniel El Fassi
CNClaus H Nielsen
Claus H Nielsen
JKJens Kjeldsen
Jens Kjeldsen
OCOle Clemmensen
Ole Clemmensen
LHLaszlo Hegedüs
Laszlo Hegedüs
In April 2005 she was diagnosed with Graves’ disease, and after uncomplicated standard methimazole therapy she received four weekly doses of 375 mg/m2 RTX from day 1 to 22 as part of a clinical trial.2 The trial was approved by the local ethics committee …

16 January 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
ASAnders Lindholm Sørensen
Anders Lindholm Sørensen
SMStine Ulrik Mikkelsen
Stine Ulrik Mikkelsen
TKTrine A. Knudsen
Trine A. Knudsen
MBMads Emil Bjørn
Mads Emil Bjørn
CAChristen Lykkegaard Andersen
Christen Lykkegaard Andersen
HHHans Carl Hasselbalch
Hans Carl Hasselbalch
We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2). The study included 32 patients with polycythemia vera and 18 with primary or secondary myelofibrosis; 46 patients were previously intolerant of or refractory to PEGIFNα2. The primary outcome was efficacy, based on hematologic parameters, quality of life measurements, and JAK2 V617F allele burden. We used the 2013 European LeukemiaNet and International Working Group- Myeloproliferative Neoplasms Research and Treatment response criteria, including response in symptoms, splenomegaly, peripheral blood counts, and bone marrow. Of 32 patients with polycythemia vera, ten (31%) achieved a remission which was a complete remission in three (9%) cases. Of 18 patients with myelofibrosis, eight (44%) achieved a remission; five (28%) were complete remissions. The cumulative incidence of peripheral blood count remission was 0.85 and 0.75 for patients with polycythemia vera and myelofibrosis, respectively. The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score decreased from 22 [95% confidence interval (95% CI):, 16-29] at baseline to 15 (95% CI: 10-22) after 2 years. The median JAK2 V617F allele burden decreased from 47% (95% CI: 33-61%) to 12% (95% CI: 6-22%), and 41% of patients achieved a molecular response. The drop-out rate was 6% among patients with polycythemia vera and 32% among those with myelofibrosis. Of 36 patients previously intolerant of PEG-IFNα2, 31 (86%) completed the study, and 24 (67%) of these received PEG-IFNα2 throughout the study. In conclusion, combination treatment improved cell counts, reduced bone marrow cellularity and fibrosis, decreased JAK2 V617F burden, and reduced symptom burden with acceptable toxicity in several patients with polycythemia vera or myelofibrosis. #EudraCT2013-003295-12.

1 July 2006 in Thyroid®
Verified
Journal Article
Closed access
DFDaniel El Fassi
Daniel El Fassi
CNClaus H. Nielsen
Claus H. Nielsen
Hans HasselbalchHans Hasselbalch
Hans Hasselbalch
LHLaszlo Hegedüs
Laszlo Hegedüs

1 March 2009 in Clinical Immunology
Verified
Journal Article
Closed access
DFDaniel El Fassi
Daniel El Fassi
JBJ. Paul Banga
J. Paul Banga
JGJacqueline A. Gilbert
Jacqueline A. Gilbert
CPCarolyn Padoa
Carolyn Padoa
LHLaszlo Hegedüs
Laszlo Hegedüs
CNClaus H. Nielsen
Claus H. Nielsen

30 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
TKTrine A. Knudsen
Trine A. Knudsen
VSVibe Skov
Vibe Skov
KSKristen E. Stevenson
Kristen E. Stevenson
LWLillian Werner
Lillian Werner
WDWilliam Duke
William Duke
AMAnn Mullally
Ann Mullally
Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencing (NGS) on 202 pretreatment samples obtained from patients with MPN enrolled in the DALIAH trial (A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms; #NCT01387763), a randomized controlled phase 3 clinical trial, and 135 samples obtained after 24 months of therapy with recombinant interferon-alpha (IFNα) or hydroxyurea. The primary aim was to evaluate the association between complete clinicohematologic response (CHR) at 24 months and molecular response through sequential assessment of 120 genes using NGS. Among JAK2-mutated patients treated with IFNα, those with CHR had a greater reduction in the JAK2 variant allele frequency (median, 0.29 to 0.07; P < .0001) compared with those not achieving CHR (median, 0.27 to 0.14; P < .0001). In contrast, the CALR variant allele frequency did not significantly decline in those achieving CHR or in those not achieving CHR. Treatment-emergent mutations in DNMT3A were observed more commonly in patients treated with IFNα compared with hydroxyurea (P = .04). Furthermore, treatment-emergent DNMT3A mutations were significantly enriched in IFNα–treated patients not attaining CHR (P = .02). A mutation in TET2, DNMT3A, or ASXL1 was significantly associated with prior stroke (age-adjusted odds ratio, 5.29; 95% confidence interval, 1.59-17.54; P = .007), as was a mutation in TET2 alone (age-adjusted odds ratio, 3.03; 95% confidence interval, 1.03-9.01; P = .044). At 24 months, we found mutation-specific response patterns to IFNα: (1) JAK2- and CALR-mutated MPN exhibited distinct molecular responses; and (2) DNMT3A-mutated clones/subclones emerged on treatment.